You are here
Articles
Posted on Thursday, January 24, 2013 - 11:00am
Funding for new research to improve leukaemia treatment by investigating how cancer cells use hiding places in the body to avoid chemotherapy drugs.
Posted on Tuesday, January 22, 2013 - 1:50pm
On 17 January 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Bosulif 100 mg and...
Posted on Tuesday, January 8, 2013 - 11:47am
Evaluation of the Impact of Switching CML Patients Treated with a First-line Tyrosine Kinase Inhibitor to Ponatinib
CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--Jan. 7, 2013-- ARIAD Pharmaceuticals, Inc. (NASDAQ:...
Posted on Friday, January 4, 2013 - 12:50pm
Paper:3782 'Change in Chronic Low-Grade Non-hematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-...
Posted on Friday, December 21, 2012 - 10:30am
Winning the battle against leukaemia: positive early results in clinical trial for DNA vaccine: News Release from University of Southampton.
Posted on Wednesday, December 19, 2012 - 7:11pm
There are a number of approaches for selective targeting of leukemic stem cells (LSCs). These include targeting stem-cell properties, such as self-renewal, inducing cycling of quiescent LSCs to sensitize them to...
Posted on Friday, December 14, 2012 - 8:09pm
FDA approves Iclusig to treat two rare types of leukemia
Drug approved 3 months ahead of schedule
The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia (...
Posted on Friday, December 14, 2012 - 10:57am
The researchers report their findings December 9 in a plenary scientific session at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta.
Posted on Monday, December 3, 2012 - 1:39pm
“This is another tool to fight this disease, but it’s the tool we’ve been waiting for,” said Brian Druker, M.D., director of the OHSU Knight Cancer Institute.
Posted on Monday, November 12, 2012 - 12:25pm
Paper46810
3743 Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study
Michael W Deininger, MD, PhD1,2,...
Posted on Thursday, November 8, 2012 - 6:55pm
'A frequent question now is whether results such as the ones reported here mean that all patients should be treated with a second-generation TKI. Taken at face value, we should always aim in cancer treatment to use our...
Posted on Saturday, October 27, 2012 - 12:53pm
Challenging Situations in the Management of Leukemias
By John M. Goldman, DM, FRCP, FRCPath, FMedSci, David Marin, MD, FRCP
Posted on Saturday, October 27, 2012 - 12:07am
Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
D J DeAngelo
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
The tyrosine kinase inhibitor (TKI)...
Posted on Wednesday, October 24, 2012 - 5:36pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 24, 2012-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for...
Posted on Wednesday, October 24, 2012 - 5:28pm
The EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial is designed to provide definitive clinical data to support regulatory approval of ponatinib in treatment-naïve CML patients. The...
- ‹ previous
- 13 of 29
- next ›